Developments in immunosuppression. Issue 1 (February 2021)

• Record Type: Journal Article
• Authors: Viklicky, Ondrej; Slatinska, Janka; Novotny, Marek; Hruba, Petra
• Is Part Of: Current opinion in organ transplantation. Volume 26:Issue 1(2021)
• Publication Date: 2021-02
• Subjects: antibody-mediated rejection -- cytomegalovirus -- donor-specific antibodies -- eculizumab -- everolimus -- kidney transplantation; Transplantation of organs, tissues, etc -- Periodicals; Immunosuppression -- Periodicals; Transplantation immunology -- Periodicals; 617.954
• DOI: 10.1097/MOT.0000000000000844
• Languages: English
• ISSNs: 1087-2418

Abstract

Abstract : Purpose of review: In this review, we discuss achievements in immunosuppression in kidney transplant recipients published at last 18 months. Recent findings: Results of recent trials with everolimus in low-risk primary kidney transplant recipients suggest that low TAC/EVR combination is noninferior and CMV and BKV viral infections are less frequent to stand TAC/MPA. Iscalimab monoclonal antibody, which prevents CD40 to CD154 binding, has just recently entered phase II clinical studies in kidney transplantation. Eculizumab, anti-C5 monoclonal antobody was recently shown to improve outcomes in DSA+ living-donor kidney transplant recipients requiring pretransplant desensitization because of crossmatch positivity. Proximal complement C1 inhibition in patients with antibody-mediated rejection was studied in several phase I trials. Summary: Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity.